<DOC>
	<DOCNO>NCT01918995</DOCNO>
	<brief_summary>This study determine safety , tolerability , pharmacokinetics two three repeat intravenous ( IV ) bolus dos regadenoson administer 10 minute apart healthy supine subject .</brief_summary>
	<brief_title>Repeat Dose Tolerance Study Regadenoson Healthy Subjects</brief_title>
	<detailed_description>All subject receive 3 dos study drug day 1 fasting food drink ( except water ) least 8 hour . Subjects remain clinic 2 day .</detailed_description>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>The subject body weight least 45 kg body mass index 18 32 kg/m2 , inclusive . QTcF must 430 msec less male 450 msec less female . If mean QTcF exceed 430 msec male 450 msec female , 1 additional triplicate measurement may take . If triplicate measurement also give abnormal QTcF result , subject exclude . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin ( TBil ) must normal range . If Screening test result AST , ALT , TBil &gt; 1 x ULN , &lt; 1.5 x ULN assessment may repeat screening period day 1 . If repeat assessment ULN , subject eligible . If AST , ALT , TBil test result Screening &gt; 1.5 x ULN , repeat , subject eligible . Female subject nonchildbearing potential childbearing potential must use highly effective birth control Screening 28 day end study . Females must breastfeed donate ova Screening 20 day end study . Male subject must use highly effective contraception Screening 90 day final study drug administration . Male subject must donate sperm start Screening 90 day final study drug administration . The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history either Short Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) . The subject positive result hepatitis B surface antigen , hepatitis C antibodies Screening know positive human immunodeficiency virus . The subject know suspect allergy regadenoson component trial product , history multiple and/or severe allergy drug food , history severe anaphylactic reaction . Subject history smoking , regardless frequency , tobacco type method intake , within 6 month prior first dose regadenoson . The subject treatment prescribe nonprescribed drug 2 week prior Day 1 , exception occasional use acetaminophen 2 g/day . The subject participate interventional clinical study receive investigational drug within 30 day 5 halflives , whichever longer , prior Screening . The subject participate prior study regadenoson . The subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen subject test positive screen Day 1 alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CVT3146</keyword>
	<keyword>Regadenoson</keyword>
</DOC>